Company news
Medicinova, Inc. (NASDAQ:MNOV) news
Medicinova, Inc. news releases on 6ix. Latest, Oct 6, 2026: MediciNova to Participate in the Maxim Growth Summit
Press releases & updates
MediciNova to Participate in the Maxim Growth Summit
October 5, 2026
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
September 29, 2026
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
September 28, 2026
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
September 24, 2026
MediciNova to Participate in Two Investor Conferences in September
September 8, 2026
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
July 15, 2026
MediciNova CEO Provides Shareholder Update
June 30, 2026
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
June 8, 2026
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
May 26, 2026
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
April 27, 2026
MediciNova to Participate at the 38th Annual ROTH Conference
March 16, 2026
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
January 29, 2026
2026 New Year’s Greetings from the CEO
January 6, 2026
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
December 18, 2025
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
December 8, 2025
Message from the CEO to MediciNova Shareholders
December 1, 2025
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
November 18, 2025
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
November 6, 2025
MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
November 4, 2025
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
October 30, 2025
MediciNova to Present at the LD Micro Main Event XIX Investor Conference
October 6, 2025
MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
September 22, 2025
MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
September 16, 2025
MediciNova Provides Shareholder Update on Key Developments
September 8, 2025
MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
August 26, 2025
MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million
July 31, 2025
MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials
July 24, 2025
MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
April 14, 2025
First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
April 8, 2025
MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
December 4, 2024
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
November 13, 2024
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
November 10, 2024
MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)
October 22, 2024
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
September 29, 2024
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
September 8, 2024
MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting
September 2, 2024
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition
August 28, 2024
MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
June 19, 2024
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
June 4, 2024
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
June 2, 2024
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
May 27, 2024
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
May 19, 2024
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
May 13, 2024
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
May 6, 2024
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
April 1, 2024
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
March 25, 2024
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
March 19, 2024
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
March 11, 2024
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
January 16, 2024